Status and phase
Conditions
Treatments
About
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Full description
This is a multinational, multicenter, double-blind, placebo-controlled study in approximately 765 participants, who will be randomized to receive a single infusion of either NTLA-2001 or placebo.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
765 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Trial Manager at Intellia
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal